Moreover, the assessment of immune-related biomarkers such as PD-L1 expression, TILs, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA) can reflect the immune status and tumor cell changes (59–61). The gene discussed is CD274; the disease is neoplasm.